Bellevue Life Sciences Faces Delisting Concerns
Ticker: OSRHW · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1840425
| Field | Detail |
|---|---|
| Company | Bellevue Life Sciences Acquisition Corp. (OSRHW) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $11.50, $50,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting-risk, material-agreement, financial-obligation
TL;DR
Bellevue Life Sciences might be delisted - big trouble.
AI Summary
Bellevue Life Sciences Acquisition Corp. filed an 8-K on April 22, 2024, reporting a material definitive agreement and a direct financial obligation. The filing also indicates a notice of delisting or failure to meet continued listing rules, suggesting potential issues with the company's stock exchange status.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact the value and liquidity of the company's stock.
Risk Assessment
Risk Level: high — The notice of delisting or failure to satisfy continued listing rules is a significant red flag for investors.
Key Players & Entities
- Bellevue Life Sciences Acquisition Corp. (company) — Filer of the 8-K
- 0001193125-24-104896 (accession_number) — SEC filing accession number
- 20240422 (date) — Filing date
FAQ
What is the nature of the material definitive agreement mentioned in the filing?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
What is the direct financial obligation or off-balance sheet arrangement?
The filing indicates the creation of such an obligation but does not provide specific details within the provided text.
What are the reasons for the notice of delisting or failure to satisfy continued listing rules?
The provided text states there is a notice of delisting or failure to satisfy continued listing rules, but does not detail the specific reasons.
When was the report filed with the SEC?
The report was filed on April 22, 2024.
What is the company's Standard Industrial Classification code?
The company's SIC code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 984 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2024-04-22 16:23:06
Key Financial Figures
- $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
- $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
- $50,000 — sory Note ") in the principal amount of $50,000 to Bellevue Global Life Sciences Invest
Filing Documents
- d828353d8k.htm (8-K) — 36KB
- d828353dex101.htm (EX-10.1) — 19KB
- 0001193125-24-104896.txt ( ) — 242KB
- blacu-20240417.xsd (EX-101.SCH) — 5KB
- blacu-20240417_def.xml (EX-101.DEF) — 15KB
- blacu-20240417_lab.xml (EX-101.LAB) — 26KB
- blacu-20240417_pre.xml (EX-101.PRE) — 16KB
- d828353d8k_htm.xml (XML) — 9KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Promissory Note, dated April 17, 2024, issued by Bellevue Life Sciences Acquisition Corp. to Bellevue Global Life Sciences Investors LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 22, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer